Novel Therapeutic Approaches in the Treatment of Multiple Myeloma and Lymphoma

Ultima Vez Modificado: 4 de enero del 2004

Share article


English

Conference Dates: Friday, February 6, 2004
Conference Location: The St. Regis Hotel, Los Angeles, CA


Sponsoring Group: Multiple Myeloma Research Foundation & Lymphoma Research Foundation

Conference Web Page URL: www.multiplemyeloma.org/events

Topics Covered: Myeloma Specific: At the completion of this program, the participants should be able to identify and describe the role and appropriate use of the following emerging treatments for multiple myeloma:

  • - Bisphosphonates and other treatments for bone disease associated with myeloma
  • - Thalidomide across the disease spectrum;
  • - Latest advances in stem cell transplant;
  • - Novel therapeutic options for the newly diagnosed patients and the relapsed/refractory patients, including Velcade and the IMiDs
Lymphoma Specific: At the completion of this program, the participants should be able to identify and describe:
  • Use of antibody therapy for the treatment of Non-Hodgkin's lymphoma
  • Advances in diagnostic approaches to Non-Hodgkins lymphoma
  • Developments in the treatment of T-cell Lymphomas
  • Advances in the treatment of Hodgkins Lymphoma

Conference Objectives:

Who Should Attend: medical oncologists, hematologist, oncology nurses and fellows

Conference Agenda:

  • 7:30  8:00 AM Breakfast and Registration
  • 8:00 AM Welcome & Introduction
  • 8:15 AM Initial Therapies in Treating Multiple Myeloma
  • 8:45 AM The Role of Transplantation in Multiple Myeloma
  • 9:15 AM Novel Therapies and Clinical Trials in Multiple Myeloma: New Paradigm For Relapsed or Refractory Patients
  • 9:45 AM The Total Patient: Advances in Bone Disease and Supportive Care Management
  • 10:15 AM Break
  • 10:30 AM Diagnostic Approaches to Non-Hodgkins Lymphoma
  • 11:00 AM An ASH Update: Antibody Therapy for Non-Hodgkin's Lymphoma
  • 11:30 AM The Role of Vaccine Therapy Non-Hodgkins Lymphoma
  • 12:00 AM Current Trends in Transplantation for Non-Hodgkins Lymphoma
  • 12:30 PM Evaluation and Adjourn

Registration Information: Contact Sara Nichols at nicholss@themmrf.org or 203-652-0206.

Continuing Education: Yes

English
News
ASH: Novel Drug Beneficial in Multiple Myeloma

Nov 23, 2014 - In patients with relapsed or resistant multiple myeloma who have received up to three prior therapies excluding the first-generation proteasome inhibitor bortezomib, treatment with the second-generation proteasome inhibitor carfilzomib is associated a high response rate and a low incidence of side effects, according to research presented at the annual meeting of the American Society of Hematology, held from Dec. 5 to 8 in New Orleans.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Frente a un nuevo diagnóstico de cáncer o de cambiar el curso de su tratamiento actual? Deje que nuestro personal de enfermería cáncer que ayudan a pasar!

Más información